Show simple item record

dc.contributor.authorO'Connor, JPB
dc.contributor.authorJayson, GC
dc.date.accessioned2020-08-12T10:55:42Z
dc.date.issued2012-12-15
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2012, 18 (24), pp. 6588 - 6598
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3927
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.ccr-12-1501
dc.description.abstractThe management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, computed tomography (CT), and ultrasound to establish proof of principle. We have reviewed published studies that used these imaging techniques to determine whether the same biomarkers relate to survival in renal, hepatocellular, and brain tumors in patients treated with VEGF inhibitors. Data show that in renal cancer, pretreatment measurements of K(trans) and early pharmacodynamic reduction in tumor enhancement and density have prognostic significance in patients treated with VEGF inhibitors. A weaker, but significant, relationship is seen with subtle early size change (10% in one dimension) and survival. Data from high-grade glioma suggest that pretreatment fractional blood volume and K(trans) were prognostic of overall survival. However, lack of control data with other therapies prevents assessment of the predictive nature of these biomarkers, and such studies are urgently required.
dc.formatPrint-Electronic
dc.format.extent6588 - 6598
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectGlioma
dc.subjectCarcinoma, Hepatocellular
dc.subjectCarcinoma, Renal Cell
dc.subjectLiver Neoplasms
dc.subjectBrain Neoplasms
dc.subjectKidney Neoplasms
dc.subjectAngiogenesis Inhibitors
dc.subjectVascular Endothelial Growth Factor A
dc.subjectTreatment Outcome
dc.subjectTumor Burden
dc.subjectBiomarkers, Tumor
dc.titleDo imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
dc.typeJournal Article
rioxxterms.versionofrecord10.1158/1078-0432.ccr-12-1501
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2012-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.issue24
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
icr.researchteamQuantitative Biomedical Imaging
dc.contributor.icrauthorO'Connor, James Patrick


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0